Authors
Latest:
Building a Key Account Organization: 5 Power QuestionsIf companies are serious about building a sustainable organization for their employees and becoming a partner to key accounts, they need to be prepared to remodel their whole business around it, writes Miranda Wheatley Price.
Latest:
Leveraging Lab Data in Advent of Personalized MarketingLaboratory testing has become a critical access point for sales teams in the age of personalized medicine.
Latest:
Piecing Together the Pricing Puzzle: The Midterm ElectionsThere is no magic bullet that will dramatically impact drug pricing to everybody’s liking. But a stepwise approach involving a series of reforms, including taking advantage of the next midterm elections, could point the path toward a solution.
Latest:
What Can Pharmaceutical Companies do to Feel Better About Reputation?Reputation Institute study finds that the reputation of pharma companies is in decline and might get worse before it gets better.
Latest:
Nurse Educators: Bridging China's Patient Care GapChina's nurse educator program aims to improve quality of care and make life simpler for physicians handling high patient load. Sebastian Bather reports.
Latest:
Pragmatic AI in PharmaRon Wince explains how Pragmatic AI allows organizations to start with the basics, create immediate business value and ROI and then increase adoption as their comfort, capabilities and confidence increases.
Latest:
Connecting the 5 Spheres of People-Based MarketingFrom persistent identity to cloud marketing driven by AI, managing holistic experience is now the hallmark of brand leadership. Croom Lawrence and Kent Groves explains how people-based marketing plays a key role.
Latest:
Can Realistic Training Devices Help Make a Blockbuster?Realistic, multisensory training devices can contribute to a drug’s reception in the eyes of both patients and healthcare practitioners, writes Paul Sullivan.
Latest:
Beyond the Merits: Generic Company Defense StrategiesJosh Reisberg outlines the foundation of a broad, overall defense strategy for generic companies embroiled in Hatch-Waxman patent infringement litigations.
Latest:
Value-Based Purchasing for Prescription Drugs Takes a Leap Forward in State MedicaidThe U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) are commitment to support value-based purchasing (VBP) of prescription drugs in Medicaid, despite headlines of CMS’s rejection of a Massachusetts request to make changes in its Medicaid prescription drug benefit.
Latest:
Pathways to Potential in Europe's Pharmerging MarketsFilip Conic outlines the market-access approaches and commercial strategies to unlock the growth potential in the Southeastern and Eastern European region.
Latest:
Patient Communications: Why Pharma Leaders Should Think Like Social MarketersBy exploring how social marketers think, pharma can unlock tried-and-tested ways to bring measurable value to their patients, writes Patrick Ladbury and Oliver Childs.
Latest:
Early-Development Strategy for PTE in Biologics Given Unknowns in the LawThe importance of early development strategy and planning for biologic patent term extension.
Latest:
A Seat at the Strategy TableHow navigating compliance risks requires so much more than policies and procedures.
Latest:
Patient & Customer-Centric CommercializationOutlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
Latest:
Patient & Customer-Centric CommercializationOutlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
Latest:
Patient & Customer-Centric CommercializationOutlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
Latest:
Early-Development Strategy for PTE in Biologics Given Unknowns in the LawThe importance of early development strategy and planning for biologic patent term extension.
Latest:
EMA Relocation Countdown: Some Industry ViewpointsRaman Sehgal talks to three industry leaders for their insights on the challenges faced across the life science sector and how the EMA needs to respond.
Latest:
The Key to Better Navigating VUCA Industry ConditionsAlison Horstmeyer discusses how pharma executives can apply four attributes of curiosity to negotiate VUCA (volatile, uncertain, complex, and ambiguous) conditions and improve organizational outcomes.
Latest:
Does the Pfizer Restructuring Make Sense?The Pfizer restructuring will be a case study in whether corporate restructuring & innovation can co-exist or whether M&A is the more viable answer, writes Edward Pratesi.
Latest:
Five Measures to Cope with the Side Effects of Health ReformWith more than 8 million Americans now signed up for health insurance through state health exchanges, The Affordable Care Act (ACA) has begun delivering benefits and new insurance protections to a large swath of Americans, many of whom had no health insurance before.
Latest:
Pharma AI Requires a New Approach to GovernanceArtificial intelligence adoption by pharma companies in the UK demands a new, agile governance layer, write Tim Wright and Antony Bott.
Latest:
Optimizing the Digital Opportunity in Biopharmaceutical R&DIf advanced technologies hold the key to at least some of the productivity issues R&D organizations need to overcome, Nicholas Lakin asks what are the best strategies and operating models for exploiting these aids to their fullest potential.
Latest:
Hitting Your Targets: A Check-up on DataProvider data delivers insights into customers and drives decisions about where to focus resources, providing opportunities for sales and marketing in life sciences.
Latest:
3 Cash-Saving Hacks for the Pharmaceutical IndustryA list of four ways the pharma industry can save money on travel-related employee expenses regarding VAT on clinical trials, clinical trial supplies, sourcing, and more.
Latest:
Hitting Your Targets: A Check-up on DataProvider data delivers insights into customers and drives decisions about where to focus resources, providing opportunities for sales and marketing in life sciences.
Latest:
Cross-Border Funding in the Life SciencesRecord capital flows across global public and private markets has opened up new channels of investment in early-stage and novel science.
